|Articles|January 18, 2020

The ID Pipeline: FDA Activity From the Week of January 12, 2020

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of January 12, 2020.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of January 12, 2020.

Novavax Granted Fast Track Designation for NanoFlu Recombinant Quadrivalent Vaccine Candidate in Older Adults

Novavax, Inc. has announced that the FDA granted Fast Track Designation for NanoFlu, a recombinant quadrivalent vaccine candidate adjuvanted with Matrix-M, in adults 65 years of age and older.

An ongoing Phase 3 clinical trial will assess the immunogenicity and safety of NanoFlu relative to the quadrivalent formulation Fluzone. Top-line clinical data is expected by the end of 2020 Q1.

Read the full press release here.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe

Related to this article

NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Measles Update: October 9, 2026
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.